Abbott Concludes Vysis Acquisition | GenomeWeb

NEW YORK, Nov. 30—Abbott Laboratories concluded its acquisition of Vysis as scheduled at midnight on November 29.

The pharmaceutical company commenced a cash tender offer on Oct. 31 to purchase all outstanding shares of the genomics-based disease management company. 

As a final step, remaining Vysis shareholders will receive the same $30.50 per share cash price as paid in the tender offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.